Roche re­leas­es more Evrys­di da­ta lead­ing up to FDA de­ci­sion for very young in­fants with SMA

One month away from an FDA de­ci­sion on Evrys­di for in­fants un­der two months old, Roche’s Genen­tech has re­leased new long-term da­ta on its oral drug for spinal mus­cu­lar at­ro­phy (SMA).

The da­ta show that, af­ter three years of treat­ment, 91% of chil­dren who be­gan tak­ing the drug at ages 1-7 months were alive (n=58). In ad­di­tion, of 48 chil­dren eval­u­at­ed, 32 main­tained and four gained the abil­i­ty to sit with­out sup­port.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER